Lang Kuhs Krystle A, Hildesheim Allan, Trabert Britton, Kemp Troy J, Purdue Mark P, Wentzensen Nicolas, Katki Hormuzd A, Pinto Ligia A, Loftfield Erikka, Safaeian Mahboobeh, Chaturvedi Anil K, Shiels Meredith S
National Cancer Institute, NIH, Bethesda, Maryland.
HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):825-32. doi: 10.1158/1055-9965.EPI-14-1363. Epub 2015 Feb 23.
Regular aspirin use may decrease cancer risk by reducing chronic inflammation. However, associations between aspirin use and circulating markers of inflammation have not been well studied.
Serum levels of 78 inflammatory markers were measured in 1,819 55- to 74-year-old men and women in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Data were combined from three completed case-control studies and reweighted to the PLCO screening arm. Self-reported aspirin and ibuprofen use (number of tablets taken per day/week/month) over the previous 12 months was collected at baseline. Associations between (i) nonregular (<4 tablets/month), (ii) low (1-4 tablets/week), (iii) moderate (1 tablet/day), or (iv) high (2+ tablets/day) regular aspirin or ibuprofen use and marker levels were assessed with weighted logistic regression.
Aspirin use was nominally associated with (Ptrend across categories ≤ 0.05) decreased levels of chemokine C-C motif ligand 15 [CCL15; OR, 0.5; 95% confidence intervals (CI), 0.3-0.8; moderate versus nonregular use]; soluble vascular endothelial growth factor receptor 2 (sVEGFR2; OR, 0.7; 95% CI, 0.4-1.0); soluble tumor necrosis factor receptor 1 (sTNFR1; OR, 0.6; 95% CI, 0.4-0.9) and increased levels of CCL13 (OR, 1.3; 95% CI, 0.8-2.1); CCL17 (OR, 1.1; 95% CI, 0.7-1.9) and interleukin 4 (IL4; OR, 1.6; 95% CI, 0.9-2.8). Trends were not statistically significant following correction for multiple comparisons. Likewise, no statistically significant associations were observed between ibuprofen use and marker levels.
No significant associations were observed between regular aspirin use and the inflammatory markers assessed.
Additional studies are needed to better understand the relationship between aspirin use, chronic inflammation, and cancer risk.
定期服用阿司匹林可能通过减轻慢性炎症来降低癌症风险。然而，阿司匹林使用与循环炎症标志物之间的关联尚未得到充分研究。
在前列腺、肺、结肠和卵巢（PLCO）癌筛查试验中，对1819名55至74岁的男性和女性测量了78种炎症标志物的血清水平。数据来自三项已完成的病例对照研究，并重新加权到PLCO筛查组。在基线时收集过去12个月内自我报告的阿司匹林和布洛芬使用情况（每天/每周/每月服用的片数）。使用加权逻辑回归评估（i）不定期（每月<4片）、（ii）低剂量（每周1 - 4片）、（iii）中等剂量（每天1片）或（iv）高剂量（每天2片以上）的定期阿司匹林或布洛芬使用与标志物水平之间的关联。
阿司匹林使用与趋化因子C - C基序配体15 [CCL15；比值比（OR），0.5；95%置信区间（CI），0.3 - 0.8；中等剂量与不定期使用相比]、可溶性血管内皮生长因子受体2（sVEGFR2；OR，0.7；95% CI，0.4 - 1.0）、可溶性肿瘤坏死因子受体1（sTNFR1；OR，0.6；95% CI，0.4 - 0.9）水平降低以及CCL13（OR，1.3；95% CI，0.8 - 2.1）、CCL17（OR，1.1；95% CI，0.7 - 1.9）和白细胞介素4（IL4；OR，1.6；95% CI，0.9 - 2.8）水平升高名义上相关（类别间趋势P≤0.05）。在进行多重比较校正后，趋势无统计学意义。同样，未观察到布洛芬使用与标志物水平之间有统计学意义的关联。
未观察到定期服用阿司匹林与所评估的炎症标志物之间有显著关联。
需要进一步研究以更好地理解阿司匹林使用、慢性炎症和癌症风险之间的关系。
